ADRA2A-VLPs Protein, Human (HEK293, His)

The ADRA2A-VLP protein represents the alpha-2 adrenergic receptor and critically mediates catecholamine-induced inhibition of adenylyl cyclase through G protein action. The order of potency of agonists includes oxymetazoline, clonidine, epinephrine, norepinephrine, phenylephrine, dopamine, p-synephrine, p-tyramine, serotonin, and p-octopamine. ADRA2A-VLPs Protein, Human (HEK293, His) is the recombinant human-derived ADRA2A-VLPs protein, expressed by HEK293 , with C-10*His labeled tag. The total length of ADRA2A-VLPs Protein, Human (HEK293, His) is 465 a.a., with molecular weight of 52.0 kDa.

ADRA2A-VLPs Protein, representing alpha-2 adrenergic receptors, play a crucial role in mediating the inhibition of adenylate cyclase induced by catecholamines through G protein action. The potency order for agonists targeting this receptor includes oxymetazoline, clonidine, epinephrine, norepinephrine, phenylephrine, dopamine, p-synephrine, p-tyramine, serotonin, and p-octopamine. Conversely, the rank order for antagonists comprises yohimbine, phentolamine, mianserine, chlorpromazine, spiperone, prazosin, propranolol, alprenolol, and pindolol. These findings delineate the pharmacological profile of ADRA2A-VLPs, shedding light on their responsiveness to various agonists and antagonists and providing insights into the intricate regulatory mechanisms governing adenylate cyclase inhibition in response to catecholamine signaling.

Human

HEK293

C-10*His

P08913 (M1-V465)

150

MFRQEQPLAEGSFAPMGSLQPDAGNASWNGTEAPGGGARATPYSLQVTLTLVCLAGLLMLLTVFGNVLVIIAVFTSRALKAPQNLFLVSLASADILVATLVIPFSLANEVMGYWYFGKAWCEIYLALDVLFCTSSIVHLCAISLDRYWSITQAIEYNLKRTPRRIKAIIITVWVISAVISFPPLISIEKKGGGGGPQPAEPRCEINDQKWYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRRGPDAVAAPPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPAPAGPRDTDALDLEESSSSDHAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGPGEERVGAAKASRWRGRQNREKRFTFVLAVVIGVFVVCWFPFFFTYTLTAVGCSVPRTLFKFFFWFGYCNSSLNPVIYTIFNHDFRRAFKKILCRGDRKRIV

52.0 kDa

/

<1 EU/μg, determined by LAL method.